桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2025-059 桂林莱茵生物科技股份有限公司 关于控股股东补充质押部分股份的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林莱茵生物科技股份有限公司（以下简称"公司"）董事会近日接到控股 股东、实际控制人秦本军先生的通知，获悉秦本军先生将其所持有的100万股公 司股份办理了补充质押，具体事项如下： 二、股东股份累计质押情况 截至公告披露日，上述股东所持质押股份情况如下： | | | | | | | | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 本次质押 | 本次质押 | 合计占 | | | | 未质押 | | | | | | | | 其所持 | 占公司 | 已 质 押 股 | | 股份限 | 占未 | | 股东 | 持股数量 | 持股 | 前质押股 | 后质押股 | | | 份 限 售 和 | 占已质 | | ...

Core Viewpoint - The company is facing multiple operational challenges, including project stagnation, declining profits, and a surge in accounts receivable, despite a seemingly smooth decision-making process regarding the change in fundraising usage [1]. Group 1: Fundraising and Project Status - In September 2022, the company raised 968 million yuan, planning to invest 730 million yuan in a "Stevia Extraction Factory" and 238 million yuan in a "Natural Health Products Research Institute" [2]. - As of June 2025, the Stevia factory project is only 77% complete and has not yet entered production, while the research institute is only 33% complete, still undergoing internal renovations [2]. - Since October 2022, the company has redirected idle fundraising to temporary liquidity support, peaking at 594 million yuan, which is 61% of the total fundraising [2]. Group 2: Financial Pressure and Debt - By Q4 2024, the company's monetary funds are only 165 million yuan, while interest-bearing liabilities amount to 823 million yuan, resulting in a funding gap of 658 million yuan [3]. - The fundraising, originally intended for construction, has been repeatedly used for debt repayment, raising questions about the company's confidence in project advancement and the true motives behind the fundraising [3]. Group 3: Revenue and Profitability Challenges - In the first half of 2025, the company achieved revenue of 837 million yuan, a year-on-year increase of 15.37%, but the net profit attributable to shareholders plummeted by 41.27% to 38.11 million yuan [4]. - The gross profit margin fell to 23.57%, and the net profit margin dropped to 5.22%, both reaching new lows [4]. - Accounts receivable surged to 722 million yuan, a year-on-year increase of 125.43%, with the ratio of accounts receivable to revenue at 86.24% [4]. Group 4: Operational Outlook - The company is grappling with a combination of weak expansion and financial pressure, which poses significant operational challenges [5]. - In a competitive market for sugar substitutes, balancing short-term debt repayment with long-term development will be a critical issue for the company [5].

一、本次变更质量控制复核人的基本情况 致同所受公司委托为公司提供2025年度财务报告及内部控制审计服务，原指 派赵雷励先生担任公司2025年度审计项目质量控制复核人，因致同所质控工作内 部调整及工作安排的需要，现指派江永辉先生担任质量控制复核人。 证券代码：002166 证券简称：莱茵生物 公告编号：2025-058 桂林莱茵生物科技股份有限公司 关于变更2025年度审计机构项目质量控制复核人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林莱茵生物科技股份有限公司（以下简称"公司"）于2025年3月26日召 开了第七届董事会第四次会议和第七届监事会第三次会议，审议通过了《关于续 聘致同会计师事务所（特殊普通合伙）为2025年度审计机构的议案》，同意公司 续聘致同会计师事务所（特殊普通合伙）（以下简称"致同所"）为公司2025 年度审计机构，该议案已于2025年4月18日经公司2024年度股东会审议通过。具 体内容详见公司于2025年3月28日在《中国证券报》《证券时报》《上海证券报》 《证券日报》及巨潮资讯网（www.cninfo.com.cn）上 ...

桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2025-057 桂林莱茵生物科技股份有限公司 关于注销非公开发行募集资金专项账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会证监许可[2021]2843 号文《关于核准桂林莱茵生 物科技股份有限公司非公开发行股票的批复》核准，并经深圳证券交易所同意， 公司非公开发行股票在深圳证券交易所上市交易。本次非公开发行人民币普通股 （A 股）165,470,085 股，发行价为每股人民币 5.85 元，本次发行共募集资金 967,999,997.25 元，扣除各项不含税发行费用 6,890,066.13 元后，募集资金净额 为 961,109,931.12 元。 上述募集资金已于 2022 年 8 月 18 日到位，募集资金到位情况已经致同会计 师事务所（特殊普通合伙）审验，并出具了致同验字（2022）第 450C000482 号 《验资报告》。 二、募集资金存放和管理情况 为了规范募集资金的管理和使用，保护投资者权益，公司依照 ...

Core Viewpoint - The recent announcements from Lain Bio have raised concerns about the company's financial health and operational challenges, particularly regarding the abrupt termination of two key projects and the redirection of raised funds to supplement working capital instead of project development [1][4]. Group 1: Project Developments - Lain Bio's natural sweetener business accounts for over 90% of its revenue, primarily from stevia and monk fruit extracts, which are popular in the sugar substitute market [2]. - The company raised 968 million yuan through a private placement in September 2022, with plans to invest 730 million yuan in a stevia extraction factory, expected to generate an additional net profit of 159 million yuan annually upon full production [2][3]. - However, as of June 2023, the stevia factory project was only 77% complete with no production or sales, while the health product research institute was only 33% complete, indicating significant delays [5][10]. Group 2: Financial Performance - In the first half of 2025, Lain Bio reported a revenue of 837 million yuan, a year-on-year increase of 15.37%, but the net profit dropped by 41.27% to 38.11 million yuan [10][12]. - The company's gross margin fell to 23.57%, down 5.03 percentage points year-on-year, and the net margin decreased to 5.22%, down 4.15 percentage points [13]. - The decline in profitability is attributed to increased competition and pricing pressures in the sweetener market, as well as rising internal costs [13]. Group 3: Cash Flow and Debt Issues - Lain Bio's accounts receivable surged to 722 million yuan, a 125.43% increase year-on-year, significantly outpacing revenue growth and raising cash flow concerns [14]. - The company's short-term borrowings reached 521 million yuan, with total interest-bearing liabilities at 867 million yuan, while cash reserves dwindled to 243 million yuan, indicating a severe liquidity crunch [16]. - The reported increase in operating cash flow by 895.28% is misleading, as it was primarily due to reduced raw material payments and one-time adjustments rather than genuine operational improvements [17][18].

Domestic News - The Ministry of Industry and Information Technology is soliciting public opinions on the mandatory national standard for "Intelligent Connected Vehicles Combination Driving Assistance System Safety Requirements," aiming to enhance safety in the intelligent connected vehicle industry [6] - The Ministry of Commerce has announced the establishment of five industry standardization technical committees, including those for the automotive circulation and resource recovery industries [7] - The Horgos Port in Xinjiang has achieved a record high in automobile exports, with 258,000 vehicles exported from January to August 2025, marking an 8.5% year-on-year increase, including 102,000 electric vehicles, which saw a 45.2% increase [8] - Dongfeng Group has formed a new joint venture with local state-owned assets in Xiangyang, with a registered capital of 8.47 billion RMB, focusing on the development and sales of intelligent vehicles [9] - Leap Motor has announced the restart of its automobile manufacturing plans in Europe, with plans to launch two new models to meet market demand starting in 2026 [10] - GAC International has launched the AION UT in Indonesia, with prices ranging from 32.5 to 36.3 million Indonesian Rupiah (approximately 140,600 to 157,000 RMB) [11] - Hello Robotaxi has received strategic investment from Alibaba, indicating a deepening collaboration in the fields of intelligent driving models and commercializing Robotaxi services [12] - CATL's sodium-ion battery can provide over 500 kilometers of pure electric range, with a density of 175Wh/kg, meeting over 40% of the domestic passenger vehicle market demand [13] International News - South Korea's electric vehicle sales from January to August 2025 reached 142,456 units, a 48.4% increase from 95,998 units in the same period last year, with electric vehicles accounting for 12.7% of new registrations [15] - Japan's exports to the U.S. have declined for five consecutive months, with an August drop of 13.8% due to decreased exports of automobiles and machinery [16] - BMW will begin production of the iX3 model in Hungary next month, with the first mass-produced vehicle expected to roll off the line by the end of 2025 [17] - Waymo has received permission to test its autonomous taxi service at San Francisco International Airport, with plans to gradually roll out commercial services [18] Commercial Vehicles - FAW Jiefang has been nominated for the fifth China Quality Award for its "12347-E2E Excellent Operation Quality Management Model," highlighting advancements in quality management within the commercial vehicle sector [20] - JD Automotive and ZF have signed a memorandum to deepen their strategic cooperation in the commercial vehicle aftermarket, aiming to create an efficient and intelligent service ecosystem [21] - China National Heavy Duty Truck Group showcased nine core products at the Liangshan Special Vehicle Exhibition, emphasizing its leadership in the transition to new energy and intelligent vehicles [22] - Qingling Group has had three products selected as major industrial technology innovation products in Chongqing, showcasing advancements in hydrogen fuel cell and specialized vehicle technology [23][24]

桂林莱茵生物科技股份有限公司 关于归还暂时补流募集资金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林莱茵生物科技股份有限公司（以下简称"公司"）于 2024 年 9 月 14 日 召开第六届董事会第三十四次会议和第六届监事会第二十九次会议，审议通过了 《关于使用部分闲置募集资金暂时补充流动资金的议案》，同意公司使用不超过 人民币 4 亿元的闲置募集资金暂时补充流动资金，使用期限自董事会审议通过之 日起不超过 12 个月，上述额度在决议有效期内可循环使用。具体内容详见公司 2024 年 9 月 18 日刊登于《中国证券报》《证券时报》《上海证券报》《证券日 报》及巨潮资讯网（www.cninfo.com.cn）的《关于使用部分闲置募集资金暂时补 充流动资金的公告》（公告编号：2024-060）。 桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2025-055 2025 年 9 月 12 日，公司已将闲置募集资金暂时补充流动资金的余额 31,060 万元全部归还至募集资金专用账户，并将归还情况通知了保荐机构及保荐 ...

公司董事长、总经理谢永富先生，董事、副总经理白昱先生，董事、副总经 理兼财务总监郑辉女士，副总经理兼董事会秘书罗华阳先生，保证向本公司提供 的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2025-056 桂林莱茵生物科技股份有限公司 关于公司部分董事、高级管理人员减持计划期限届满 未减持公司股份的公告 桂林莱茵生物科技股份有限公司（以下简称"公司"）于 2025 年 5 月 22 日 披露了《关于公司部分董事、高级管理人员减持股份的预披露公告》（公告编号： 2025-036），公司董事长、总经理谢永富先生，董事、副总经理白昱先生，董事、 副总经理兼财务总监郑辉女士，副总经理兼董事会秘书罗华阳先生（以下简称"上 述人员"）拟自减持计划公告披露之日起 15 个交易日后 3 个月内以集中竞价交 易方式减持其所持有的部分公司股份合计不超过 1,018,500 股，占公司总股本的 比例为 0.14%（总股本系扣除公司回购专用证券账户上已回购股份后的数 ...

桂林莱茵生物科技股份有限公司 桂林莱茵生物科技股份有限公司 2025年第一次临时股东会决议公告 证券代码：002166 证券简称：莱茵生物 公告编号：2025-054 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议的召开情况 1、会议届次：2025年第一次临时股东会 2、会议召集人：公司第七届董事会，公司第七届董事会第六次会议决议召 开本次股东会。 3、会议召开方式：现场表决与网络投票相结合，股东应选择现场投票、网 络投票中的一种方式，如果同一表决权出现重复投票表决的，以第一次投票表决 结果为准。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会无否决提案的情形； 4、会议时间及地点： 现场会议的召开时间为2025年9月9日下午15:00，现场会议的召开地点为桂 林市临桂区人民南路19号公司四楼会议室。 桂林莱茵生物科技股份有限公司（以下简称"公司"）2025 年第一次临时股 东会以现场表决与网络投票相结合的方式召开，出席公司本次股东会的股东及股 东代理人共计 302 名，代表股份 317,002,001 股，占公司有表决 ...

北京德恒律师事务所 关于桂林莱茵生物科技股份有限公司 2025 年第一次临时股东会的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 北京德恒律师事务所 关于桂林莱茵生物科技股份有限公司 2025 年第一次临时股东会的法律意见 北京德恒律师事务所 关于桂林莱茵生物科技股份有限公司 2025 年第一次临时股东会的 法律意见 致：桂林莱茵生物科技股份有限公司 桂林莱茵生物科技股份有限公司（以下简称"公司"）2025 年第一次临时 股东会（以下简称"本次会议"）于 2025 年 9 月 9 日（星期二）召开。北京德 恒律师事务所接受公司委托，指派李哲律师、王冰律师（以下简称"德恒律师"） 出席本次会议。根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规 则》（以下简称"《股东会规则》"）、《桂林莱茵生物科技股份有限公司章程》 （以下简称"《公司章程》"）的规定，德恒律师就本次会议的召集、召开程序、 现场出席会议人员资格、表决程序等相关事项 ...